The AMRF is committed to funding research aimed at furthering knowledge and offering better outcomes in the prevention, diagnosis and treatment of melanoma.
Our aim is to support research that leads to a reduction in the incidence of melanoma and its impact on those living with the cancer.
The AMRF will focus on supporting early career researchers in Australia.
The Foundation has established an evaluation framework to assist in the identification of the key research areas to optimise our funding support.
Over the past few years the AMRF has provided funding to support research that has had a positive impact for some with melanoma.
Current Research Projects being funded:
- Improving Melanoma Therapy Using Timed Coordinated Vaccine & Chemotherapy Delivery: Timed vs Untimed VMCL Melanoma Vaccine Therapy Phase III Study for Patients with Advanced Stage IV Melanoma: Chief Investigator Prof Brendon Coventry, University of Adelaide.
- Targeting EPHB4 with bovine antibodies to cure melanoma – Dr Pablo Garcia Valtanen, Postdoctoral Research Associate at the School of Pharmacy and Medical Sciences, University of South Australia Cancer Research Institute.
Funding from the AMRF is supporting a PhD student to conduct laboratory tests towards a new treatment method to complement existing chemotherapy drugs.
Previously funded research projects include:
- Analysis of the completed EMOTIV (“Enhancing Melanoma Outcomes using a Timed Immunotherapy Vaccine”) Melanoma Vaccine Study
- Analysis of the cyclical behaviours of the human immune system as it effects vaccine therapies
- Analysis of the long-term survival outcomes in the VMCL (“Vaccinia Melanoma Cell Lysate”) Trial
- The effect of timing on the IL-2 (“Interleukin-2 Melanoma Therapy”)